Can you provide the average price target for PHARMANUTRA SPA stock?
7 analysts have analysed PHN.MI and the average price target is 88.74 EUR. This implies a price increase of 8.62% is expected in the next year compared to the current price of 81.7.
PHARMANUTRA SPA (PHN.MI) Forecast, Price Target & Analyst Ratings
BIT:PHN • IT0005274094
Current stock price
81.7 EUR
0 (0%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMANUTRA SPA (PHN.MI).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
€88.74
Upside
+ 8.62%
From current price of €81.70 to mean target of €88.74, Based on 7 analyst forecasts
Low
€85.85
Median
€88.74
High
€93.45
Price Target Revisions
1 Month
5.67%
3 Months
7.41%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for PHN.MI. The average price target is 88.74 EUR. This implies a price increase of 8.62% is expected in the next year compared to the current price of 81.7.
The average price target has been revised upward by 7.41% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
PHN.MI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about PHN.MI.
In the previous month the buy percentage consensus was at a similar level.
PHN.MI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
2.53%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 82.724M 21.45% | 100.202M 21.13% | 115.498M 15.27% | 133.6M 15.67% | 153.35M 14.78% | 176.37M 15.01% | 203.78M 15.54% | 204.81M 0.51% | 219.58M 7.21% | 233.53M 6.35% | 246.67M 5.63% | 255.12M 3.43% | |
| EBITDA YoY % growth | 24.392M 20.10% | 26.512M 8.69% | 31.575M 19.10% | 34.277M 8.56% | 41.235M 20.30% | 48.666M 18.02% | 59.369M 21.99% | 54.022M -9.01% | 57.644M 6.70% | 61.165M 6.11% | 64.384M 5.26% | 67.301M 4.53% | |
| EBIT YoY % growth | 23.074M 21.95% | 23.388M 1.36% | 27.646M 18.21% | 29.708M 7.46% | 36.087M 21.47% | 43.7M 21.10% | 48.278M 10.48% | 50.515M 4.63% | 53.978M 6.86% | 57.237M 6.04% | 60.292M 5.34% | 62.171M 3.12% | |
| Operating Margin | 27.89% | 23.34% | 23.94% | 22.24% | 23.53% | 24.78% | 23.69% | 24.66% | 24.58% | 24.51% | 24.44% | 24.37% | |
| EPS YoY % growth | 1.56 15.55% | 1.33 -14.74% | N/A 43.02% | 2.03 6.55% | 2.57 26.58% | 3.10 21.00% | 3.51 13.23% | N/A | N/A | N/A | N/A | N/A |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.48%
EPS Next 5 Year
21.45%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
15.33%
Revenue Next 5 Year
15.31%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
20.22%
EBIT Next 5 Year
14.04%
PHARMANUTRA SPA / PHN.MI Forecast FAQ
When does PHARMANUTRA SPA (PHN.MI) report earnings?
PHARMANUTRA SPA (PHN.MI) will report earnings on 2026-05-11.
Can you provide the consensus rating for PHARMANUTRA SPA stock?
The consensus rating for PHARMANUTRA SPA (PHN.MI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.